Company profile
UK company 13408581, incorporated on 19 May 2021.
Synteny
Synteny Biotechnology Limited is a UK company with status active founded in 2021 based in London.
Company number 13408581
Financial period: 1 Feb 2025 to 31 Jan 2026
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
At Synteny Biotechnology, we propose a radically new approach for early cancer detection. Instead of detecting cancer directly, we propose to harness the adaptive immune system to detect it for us. By "reading out" what the immune system is recognising via a simple blood test, we propose to harness the body's in-built diagnostic to detect cancer anywhere in the body. Two features of the immune system make it an ideal detector of early cancer. First, it is exquisitely sensitive: able to detect a single molecule of a foreign antigen caused by, for example, a tumour or a viral infection. Second, the immune system amplifies an initially weak signal by exponentially expanding the immune cells that successfully recognise the tumour. We are establishing machine learning methods for "decoding" the immune system and use these methods to develop an accurate and cheap pan-cancer early detection test. We have raised in excess of £1.2m in an initial seed round from both angel investors and a Innovate UK Biomedical Catalyst award.
Our current impact is providing full-time employment to 2 machine learning engineers. This is expected to grow to 5 FTE in the next few months.
1 May 2022 to 31 Jul 2023
The NHS (and every healthcare provider globally) are struggling to improve outcomes for people with cancer. People are far more likely to survive cancer if it's detected before it advances and spreads, because treatments work better. Only 55% of people in the UK currently seek treatment when their cancer is at StageI or Stage II. Introducing screening pro...
